| scholarly article | Q13442814 |
| P356 | DOI | 10.1017/ERM.2017.2 |
| P698 | PubMed publication ID | 28162121 |
| P2093 | author name string | C Gartzonika | |
| D Tsakogiannis | |||
| P Markoulatos | |||
| S Levidiotou-Stefanou | |||
| P2860 | cites work | Comparison of next-generation sequencing systems | Q21296690 |
| Global cancer statistics | Q22241238 | ||
| A review of the clinical performance of the Aptima HPV assay | Q26776336 | ||
| Next-generation sequencing in clinical virology: Discovery of new viruses | Q26797795 | ||
| Real-time PCR in clinical microbiology: applications for routine laboratory testing | Q27472851 | ||
| The Role of the DNA Damage Response throughout the Papillomavirus Life Cycle | Q28081948 | ||
| Common fragile sites are preferential targets for HPV16 integrations in cervical tumors | Q28212477 | ||
| The impact of next-generation sequencing technology on genetics | Q28268088 | ||
| Classification of papillomaviruses | Q29618731 | ||
| Sanger DNA-sequencing reactions performed in a solid-phase nanoreactor directly coupled to capillary gel electrophoresis | Q31994506 | ||
| Clinical performance of Roche Cobas 4800 HPV Test | Q33703374 | ||
| Sensitive simultaneous detection of seven sexually transmitted agents in semen by multiplex-PCR and of HPV by single PCR. | Q33748402 | ||
| Analysis of host-parasite incongruence in papillomavirus evolution using importance sampling | Q33860365 | ||
| HPV-16 E2 gene disruption and sequence variation in CIN 3 lesions and invasive squamous cell carcinomas of the cervix: relation to numerical chromosome abnormalities. | Q33918562 | ||
| Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique | Q33951730 | ||
| Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments | Q34021545 | ||
| E1-mediated recruitment of a UAF1-USP deubiquitinase complex facilitates human papillomavirus DNA replication | Q34057851 | ||
| Non-random integration of the HPV genome in cervical cancer | Q34326351 | ||
| Bead-based multiplex genotyping of human papillomaviruses | Q34430808 | ||
| Real-time PCR for mRNA quantitation | Q34439106 | ||
| Development of a multiplex methylation-specific PCR as candidate triage test for women with an HPV-positive cervical scrape | Q34486779 | ||
| Coming of age: ten years of next-generation sequencing technologies | Q34526801 | ||
| A DNA methylation classifier of cervical precancer based on human papillomavirus and human genes | Q34531028 | ||
| Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer | Q34596772 | ||
| Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer. | Q34680748 | ||
| A population-based observational study comparing Cervista and Hybrid Capture 2 methods: improved relative specificity of the Cervista assay by increasing its cut-off | Q34789131 | ||
| Comparison of the accuracy of Hybrid Capture II and polymerase chain reaction in detecting clinically important cervical dysplasia: a systematic review and meta-analysis | Q34913072 | ||
| Detection and typing of low-risk human papillomavirus genotypes HPV 6, HPV 11, HPV 42, HPV 43 and HPV 44 by polymerase chain reaction and restriction fragment length polymorphism. | Q54419351 | ||
| Human papillomavirus 16 load and E2/E6 ratio in HPV16-positive women: biomarkers for cervical intraepithelial neoplasia >or=2 in a liquid-based cytology setting? | Q54457234 | ||
| Detection and typing of human papillomaviruses combining different methods: polymerase chain reaction, restriction fragment length polymorphism, line probe assay and sequencing. | Q54518397 | ||
| Genotyping of human papillomavirus in cervical lesions by L1 consensus PCR and the Luminex xMAP system. | Q54602336 | ||
| Hybrid capture 2 viral load and the 2-year cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer. | Q54693070 | ||
| Comparison of five different polymerase chain reaction methods for detection of human papillomavirus in cervical cell specimens | Q57937563 | ||
| Increased Risk for Cervical Disease Progression of French Women Infected with the Human Papillomavirus Type 16 E6-350G Variant | Q58281225 | ||
| Human Papillomavirus (HPV) Detection Using In Situ Hybridization in Histologic Samples | Q58390369 | ||
| Restriction-site PCR: a direct method of unknown sequence retrieval adjacent to a known locus by using universal primers | Q70463883 | ||
| The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR | Q73108013 | ||
| High sensitivity of PCR in situ hybridization for the detection of human papillomavirus infection in uterine cervical neoplasias | Q74449009 | ||
| HPV16 and HPV18 in genital tumors: Significantly different levels of viral integration and correlation to tumor invasiveness | Q74457069 | ||
| Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade | Q76383182 | ||
| Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia | Q78761510 | ||
| HPV prevalence, viral load and physical state of HPV-16 in cervical smears of patients with different grades of CIN | Q80686680 | ||
| A population-based clinical trial comparing endocervical high-risk HPV testing using hybrid capture 2 and Cervista from the SHENCCAST II Study | Q83896917 | ||
| Analytical performance of the Investigational Use Only Cervista HPV HR test as determined by a multi-center study | Q84341102 | ||
| Comparison of the PapilloCheck® assay with the digene HC2 HPV DNA assay for the detection of 13 high-risk human papillomaviruses in cervical and anal scrapes | Q84374371 | ||
| Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study | Q84818275 | ||
| In Situ Detection of Human Papillomavirus DNA After PCR-Amplification | Q85181736 | ||
| Detection of the human papillomavirus 58 physical state using the amplification of papillomavirus oncogene transcripts assay | Q86295498 | ||
| Comparison of the clinical performances of the AdvanSure HPV Screening Real-Time PCR, the Abbott Real-Time High-Risk HPV Test, and the Hybrid Capture High-Risk HPV DNA Test for Cervical Cancer Screening | Q87846904 | ||
| Next generation sequencing in women affected by nonsyndromic premature ovarian failure displays new potential causative genes and mutations. | Q39004927 | ||
| Preferential sites for the integration and disruption of human papillomavirus 16 in cervical lesions | Q39216266 | ||
| Comparison of analytical and clinical performances of the digene HC2 HPV DNA assay and the INNO-LiPA HPV genotyping assay for detecting high-risk HPV infection and cervical neoplasia among HIV-positive African women | Q39301786 | ||
| Frequent genomic structural alterations at HPV insertion sites in cervical carcinoma | Q39696315 | ||
| A simple method for the detection and genotyping of high-risk human papillomavirus using seminested polymerase chain reaction and reverse hybridization. | Q40482493 | ||
| The reliability of high-risk human papillomavirus detection by Aptima HPV assay in women with ASC-US cytology | Q40698187 | ||
| Clinical and analytical performance of the PapilloCheck HPV-Screening assay using the VALGENT framework | Q40719015 | ||
| Methylation and expression of miRNAs in precancerous lesions and cervical cancer with HPV16 infection | Q40822201 | ||
| Simultaneous detection of human papillomavirus integration and c-MYC gene amplification in cervical lesions: an emerging marker for the risk to progression | Q41028798 | ||
| Evaluation of the HPV typing INNO-LiPA EXTRA assay on formalin-fixed paraffin-embedded cervical biopsy samples | Q41624543 | ||
| A real-time PCR approach based on SPF10 primers and the INNO-LiPA HPV genotyping extra assay for the detection and typing of human papillomavirus | Q41687620 | ||
| Multiplex PCR assay for the rapid identification of human papillomavirus genotypes 16, 18, 45, 35, 66, 33, 51, 58, and 31 in clinical samples. | Q41689179 | ||
| Duplex Real-time PCR assay and SYBR green I melting curve analysis for molecular identification of HPV genotypes 16, 18, 31, 35, 51 and 66. | Q41716414 | ||
| Determination of human papillomavirus 16 physical status through E1/E6 and E2/E6 ratio analysis. | Q41742611 | ||
| Sites of disruption within E1 and E2 genes of HPV16 and association with cervical dysplasia. | Q41749132 | ||
| Analytical performance of newly developed multiplex human papillomavirus genotyping assay using Luminex xMAP™ technology (Mebgen™ HPV Kit). | Q42217712 | ||
| Simple and rapid human papillomavirus genotyping method by restriction fragment length polymorphism analysis with two restriction enzymes. | Q42252309 | ||
| Oncogenic human papillomavirus genotyping by multiplex PCR and fragment analysis | Q42258252 | ||
| High-risk human papillomavirus is transcriptionally active in a subset of sinonasal squamous cell carcinomas | Q42270066 | ||
| Human papillomavirus multiplex ligation-dependent probe amplification assay for the assessment of viral load, integration, and gain of telomerase-related genes in cervical malignancies. | Q42275018 | ||
| Molecular and evolutionary analysis of HPV16 E6 and E7 genes in Greek women. | Q42276651 | ||
| Comparative study of the cervista and hybrid capture 2 methods in detecting high-risk human papillomavirus in cervical lesions | Q42279932 | ||
| Comparison of the analytical and clinical performances of Abbott RealTime High Risk HPV, Hybrid Capture 2, and DNA Chip assays in gynecology patients | Q42288965 | ||
| HPV in situ hybridization signal patterns as a marker for cervical intraepithelial neoplasia progression | Q42444873 | ||
| The majority of viral-cellular fusion transcripts in cervical carcinomas cotranscribe cellular sequences of known or predicted genes | Q42650642 | ||
| A new PCR-based assay amplifies the E6-E7 genes of most mucosal human papillomaviruses (HPV). | Q43881556 | ||
| Disruption of HPV 16 E1 and E2 genes in precancerous cervical lesions | Q44164508 | ||
| The physical state of HPV16 infection and its clinical significance in cancer precursor lesion and cervical carcinoma | Q44261669 | ||
| p16INK4A immunohistochemistry is superior to HPV in situ hybridization for the detection of high-risk HPV in atypical squamous metaplasia | Q44387447 | ||
| HPV in situ hybridization: impact of different protocols on the detection of integrated HPV. | Q44506678 | ||
| Human papillomavirus detection and typing using a nested-PCR-RFLP assay | Q44751201 | ||
| Identification of human papillomavirus type 16 integration sites in high-grade precancerous cervical lesions | Q44947877 | ||
| Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study | Q45206974 | ||
| Comparison of polymerase chain reaction and catalyzed signal amplification in situ hybridization methods for human papillomavirus detection in paraffin-embedded cervical preneoplastic and neoplastic lesions | Q45211394 | ||
| Comparison between hybrid capture II and polymerase chain reaction results among women at low risk for cervical cancer | Q45219192 | ||
| Sequence variation analysis of the E2 gene of human papilloma virus type 16 in cervical lesions from women in Greece | Q45360017 | ||
| Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study | Q46295268 | ||
| Preferential integration of human papillomavirus type 18 near the c-myc locus in cervical carcinoma. | Q47439834 | ||
| A comprehensive analysis of HPV integration loci in anogenital lesions combining transcript and genome-based amplification techniques. | Q47821772 | ||
| Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication | Q47860026 | ||
| Restriction fragment length polymorphism of L1 amplicon using Rsa 1 detects five different human papillomavirus types and their co-infections among women attending a gynaecological outpatient department | Q47956444 | ||
| Human papillomavirus typing with a polymerase chain reaction-based genotyping array compared with type-specific PCR. | Q50082493 | ||
| Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high-grade cervical lesions. | Q50676894 | ||
| Polymerase chain reaction-based fluorescent Luminex assay to detect the presence of human papillomavirus types. | Q51580698 | ||
| Performance of the Abbott RealTime high-risk HPV test in women with abnormal cervical cytology smears. | Q51693574 | ||
| Accurate human papillomavirus genotyping by 454 pyrosequencing. | Q51878755 | ||
| Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-Results from the Hammersmith study. | Q51895139 | ||
| Disruption of the E1 and E2 reading frames of HPV 16 in cervical carcinoma is associated with poor prognosis. | Q52530292 | ||
| Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. | Q52584352 | ||
| Integration of human papillomavirus type-16 and type-18 is a very early event in cervical carcinogenesis. | Q53224037 | ||
| Comparison of HPV genotyping by type-specific PCR and sequencing. | Q53301243 | ||
| Next generation sequencing technology: Advances and applications. | Q53509800 | ||
| Multiplex nested PCR (MNP) assay for the detection of 15 high risk genotypes of human papillomavirus. | Q53674552 | ||
| Clinical performance of the CLART human papillomavirus 2 assay compared with the hybrid capture 2 test. | Q54395822 | ||
| Identification of rearranged sequences of HPV16 DNA in precancerous and cervical cancer cases | Q38815132 | ||
| Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism | Q38920757 | ||
| Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with the linear array HPV genotyping PCR assay and influence of DNA extraction method on HPV detection | Q35066537 | ||
| Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the roche linear array HPV genotyping test | Q35073364 | ||
| Small molecule inhibitors of human papillomavirus protein - protein interactions | Q35107717 | ||
| HPV E6/E7 RNA in situ hybridization signal patterns as biomarkers of three-tier cervical intraepithelial neoplasia grade | Q35119921 | ||
| Comparison of human papillomavirus detection by Aptima HPV and cobas HPV tests in a population of women referred for colposcopy following detection of atypical squamous cells of undetermined significance by Pap cytology | Q35193205 | ||
| Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation | Q35196630 | ||
| Ten years of next-generation sequencing technology | Q35222334 | ||
| Comparison of analytical and clinical performance of CLART HPV2 genotyping assay to Linear Array and Hybrid Capture 2: a split-sample study | Q35342179 | ||
| Clinical validation of the cobas 4800 HPV test for cervical screening purposes. | Q35530540 | ||
| Evolution and classification of oncogenic human papillomavirus types and variants associated with cervical cancer | Q35619122 | ||
| Novel microsphere-based method for detection and typing of 46 mucosal human papillomavirus types | Q35689082 | ||
| Detection and typing of human papillomavirus by e6 nested multiplex PCR | Q35716913 | ||
| Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract | Q35789790 | ||
| Routine human papillomavirus genotyping by DNA sequencing in community hospital laboratories | Q35847330 | ||
| Comparison of the AdvanSure human papillomavirus screening real-time PCR, the Abbott RealTime High Risk human papillomavirus test, and the Hybrid Capture human papillomavirus DNA test for the detection of human papillomavirus | Q35919848 | ||
| NGS-based approach to determine the presence of HPV and their sites of integration in human cancer genome. | Q36086852 | ||
| HPV detection methods in head and neck cancer | Q36088064 | ||
| Chromosomal biomarkers for detection of human papillomavirus associated genomic instability in epithelial cells of cervical cytology specimens | Q36103433 | ||
| Human papillomavirus genotyping by Linear Array and Next-Generation Sequencing in cervical samples from Western Mexico | Q36131433 | ||
| The PapilloCheck Assay for Detection of High-Grade Cervical Intraepithelial Neoplasia | Q36173887 | ||
| Papillomaviruses: different genes have different histories. | Q36266681 | ||
| Genome variation of human papillomavirus types: phylogenetic and medical implications | Q36332540 | ||
| Comparative study of HPV16 integration in cervical lesions between ethnicities with high and low rates of infection with high-risk HPV and the correlation between integration rate and cervical neoplasia | Q36334581 | ||
| A Suggested Approach to Simplify and Improve Cervical Screening in the United States | Q36407125 | ||
| Clinical validation of a type-specific real-time quantitative human papillomavirus PCR against the performance of hybrid capture 2 for the purpose of cervical cancer screening. | Q36414150 | ||
| Evaluation of a commercialized in situ hybridization assay for detecting human papillomavirus DNA in tissue specimens from patients with cervical intraepithelial neoplasia and cervical carcinoma | Q36423738 | ||
| A review of methods for detect human Papillomavirus infection | Q36427451 | ||
| Molecular biology of human papillomavirus infection and cervical cancer | Q36441612 | ||
| Use of multiple PCR primer sets for optimal detection of human papillomavirus | Q36537504 | ||
| Genotyping of human papillomaviruses by a novel one-step typing method with multiplex PCR and clinical applications | Q36539744 | ||
| Human papillomavirus (HPV) genome status & cervical cancer outcome--A retrospective study | Q36550149 | ||
| Type distribution, viral load and integration status of high-risk human papillomaviruses in pre-stages of cervical cancer (CIN). | Q36616056 | ||
| Uneven distribution of HPV 16 E6 prototype and variant (L83V) oncoprotein in cervical neoplastic lesions | Q36641924 | ||
| Development and characterization of the cobas human papillomavirus test | Q36826712 | ||
| Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? | Q36851090 | ||
| Detection and typing of human papilloma virus by multiplex PCR with type-specific primers. | Q36857709 | ||
| Sequencing-based genotyping of mixed human papillomavirus infections by use of RipSeq software | Q36884342 | ||
| Analysis of human papillomavirus type 16 (HPV16) DNA load and physical state for identification of HPV16-infected women with high-grade lesions or cervical carcinoma. | Q36957989 | ||
| Genotyping human papillomaviruses: development and evaluation of a comprehensive DNA microarray | Q36961238 | ||
| Fibroblast growth factors and Hedgehogs: at the heart of the epicardial signaling center | Q37022199 | ||
| Sequence variation of human papillomavirus type 16 and measurement of viral integration by quantitative PCR. | Q37116735 | ||
| Landscape of DNA virus associations across human malignant cancers: analysis of 3,775 cases using RNA-Seq | Q37123281 | ||
| Detection of human papillomavirus DNA in cervical samples: analysis of the new PGMY-PCR compared to the hybrid capture II and MY-PCR assays and a two-step nested PCR assay | Q37157249 | ||
| A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study | Q37165122 | ||
| Looking ahead: a case for human papillomavirus testing of self-sampled vaginal specimens as a cervical cancer screening strategy | Q37195121 | ||
| The papillomavirus E2 proteins | Q37198619 | ||
| Analysis of HPV16, 18, 31, and 35 DNA in pre-invasive and invasive lesions of the uterine cervix | Q37210134 | ||
| Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study | Q37271280 | ||
| Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types | Q37295681 | ||
| Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears | Q37310663 | ||
| The cytology and DNA detection by the PapilloCheck(®) test in the diagnosis of human papillomavirus infection | Q37319972 | ||
| The human papillomavirus E7 oncoprotein | Q37325199 | ||
| Papillomavirus E6 proteins | Q37350446 | ||
| Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older | Q37461977 | ||
| Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability | Q37550193 | ||
| Viral load, gene expression and mapping of viral integration sites in HPV16-associated HNSCC cell lines. | Q37726485 | ||
| Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology | Q37757640 | ||
| Human papillomavirus oncoproteins: pathways to transformation | Q37769103 | ||
| Introduction of human papillomavirus DNA screening in the world: 15 years of experience | Q38064059 | ||
| Global burden of human papillomavirus and related diseases. | Q38064060 | ||
| The biology and life-cycle of human papillomaviruses. | Q38064068 | ||
| Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials | Q38160099 | ||
| The human papillomavirus family and its role in carcinogenesis | Q38169482 | ||
| DNA polymerases drive DNA sequencing-by-synthesis technologies: both past and present | Q38227870 | ||
| Next-generation sequencing technologies: breaking the sound barrier of human genetics | Q38242485 | ||
| FHACT: the FISH-based HPV-associated cancer test that detects nonrandom gain at four genomic loci as biomarkers of disease progression | Q38259453 | ||
| Digene HPV Genotyping RH Test RUO: comparative evaluation with INNO-LiPA HPV Genotyping Extra Test for detection of 18 high-risk and probable high-risk human papillomavirus genotypes. | Q38492987 | ||
| Biological implications and therapeutic significance of DNA methylation regulated genes in cervical cancer. | Q38689782 | ||
| P921 | main subject | genotyping | Q912147 |
| P304 | page(s) | e1 | |
| P577 | publication date | 2017-02-06 | |
| P1433 | published in | Expert Reviews in Molecular Medicine | Q15755244 |
| P1476 | title | Molecular approaches for HPV genotyping and HPV-DNA physical status | |
| P478 | volume | 19 |
| Q47370960 | Association of p16 (CDKN2A) polymorphisms with the development of HPV16-related precancerous lesions and cervical cancer in the Greek population. |
| Q101574294 | HRRD: a manually-curated database about the regulatory relationship between HPV and host RNA |
| Q64966546 | Screening for Human Papillomavirus in a Low- and Middle-Income Country. |
Search more.